Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653626 | 0.90 | SYK (0.61) | ROCK2ROCK1SYKCDC7 | |
| SCHEMBL16638034 | 0.86 | ROCK2 (0.64) | ROCK2ROCK1MKNK1CDC7 | |
| SCHEMBL1973780 | 0.85 | SYK (0.77) | ROCK2ROCK1SYKMKNK1CDC7 | |
| SCHEMBL2442475 | 0.84 | MKNK1 (0.59) | ROCK2ROCK1SYKMKNK1CDC7 | |
| SCHEMBL15639737 | 0.84 | MKNK1 (0.55) | ROCK2ROCK1MKNK1 | |
| SCHEMBL657771 | 0.84 | SYK (0.69) | ROCK2ROCK1SYKCDC7 | |
| SCHEMBL24271216 | 0.84 | ROCK2 (0.60) | ROCK2ROCK1MKNK1CDC7 | |
| SCHEMBL657477 | 0.83 | SYK (0.67) | ROCK2ROCK1SYKCDC7 | |
| SCHEMBL2104626 | 0.83 | SYK (0.67) | ROCK2ROCK1SYKCDC7 | |
| SCHEMBL2102889 | 0.83 | SYK (0.67) | ROCK2ROCK1SYKCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | claimed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| CN-111587112-B | Rho-related inhibitors of coiled-coil-containing protein kinases | 卡德门企业有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230174519-A1 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | KADMON CORPORATION, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-11613531-B2 | Inhibitors of RHO associated coiled-coil containing protein kinase | KADMON CORPORATION, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174519-A1 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885SYK 1585/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885SYK 378/4885 |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | ROCK2 1903/4885ROCK1 2628/4885SYK 54/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | ROCK2 2518/4885ROCK1 2520/4885SYK 251/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | ROCK2 2281/4885ROCK1 3504/4885SYK 42/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | ROCK2 2740/4885ROCK1 2519/4885SYK 83/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | ROCK2 1903/4885ROCK1 2628/4885SYK 54/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885SYK 456/4885 |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | HRH4, FCER2, HRH2 | ROCK2 2657/4885ROCK1 2891/4885SYK 78/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | ROCK2 1194/4885ROCK1 955/4885SYK 1/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885SYK 317/4885 |
| US-11613531-B2 | Inhibitors of RHO associated coiled-coil containing protein kinase | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885SYK 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.